image
Healthcare - Medical - Diagnostics & Research - NASDAQ - US
$ 1.58
-7.06 %
$ 588 M
Market Cap
-2.29
P/E
1. INTRINSIC VALUE

Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays.[ Read More ]

The intrinsic value of one LAB stock under the base case scenario is HIDDEN Compared to the current market price of 1.58 USD, Standard BioTools Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart LAB

image
FINANCIALS
106 M REVENUE
8.57%
-76.6 M OPERATING INCOME
34.08%
-74.7 M NET INCOME
60.73%
-43.3 M OPERATING CASH FLOW
51.56%
20.2 M INVESTING CASH FLOW
122.96%
-6.81 M FINANCING CASH FLOW
-2.95%
45 M REVENUE
20.87%
-31.7 M OPERATING INCOME
24.46%
-26.9 M NET INCOME
41.08%
-27.9 M OPERATING CASH FLOW
28.63%
-30.9 M INVESTING CASH FLOW
-61.45%
-2 K FINANCING CASH FLOW
99.99%
Balance Sheet Decomposition Standard BioTools Inc.
image
Current Assets 158 M
Cash & Short-Term Investments 115 M
Receivables 19.7 M
Other Current Assets 23.7 M
Non-Current Assets 165 M
Long-Term Investments 0
PP&E 54.8 M
Other Non-Current Assets 110 M
Current Liabilities 109 M
Accounts Payable 9.24 M
Short-Term Debt 68.2 M
Other Current Liabilities 31.9 M
Non-Current Liabilities 50.5 M
Long-Term Debt 34.4 M
Other Non-Current Liabilities 16.2 M
EFFICIENCY
Earnings Waterfall Standard BioTools Inc.
image
Revenue 106 M
Cost Of Revenue 55.9 M
Gross Profit 50.4 M
Operating Expenses 113 M
Operating Income -76.6 M
Other Expenses -1.94 M
Net Income -74.7 M
RATIOS
47.44% GROSS MARGIN
47.44%
-72.03% OPERATING MARGIN
-72.03%
-70.21% NET MARGIN
-70.21%
-45.74% ROE
-45.74%
-23.11% ROA
-23.11%
-33.36% ROIC
-33.36%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Standard BioTools Inc.
image
Net Income -74.7 M
Depreciation & Amortization 15.2 M
Capital Expenditures -2.83 M
Stock-Based Compensation 13.1 M
Change in Working Capital 1.79 M
Others 9.35 M
Free Cash Flow -46.1 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Standard BioTools Inc.
image
Wall Street analysts predict an average 1-year price target for LAB of $3.25 , with forecasts ranging from a low of $3.25 to a high of $3.25 .
LAB Lowest Price Target Wall Street Target
3.25 USD 105.70%
LAB Average Price Target Wall Street Target
3.25 USD 105.70%
LAB Highest Price Target Wall Street Target
3.25 USD 105.70%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Standard BioTools Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
4.44 M USD 1
0-3 MONTHS
12.1 M USD 1
3-6 MONTHS
1.93 M USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
2 months ago
Aug 27, 2024
Bought 547 K USD
Casdin Partners Master Fund, L.P.
director, 10 percent owner:
+ 250000
2.187 USD
2 months ago
Aug 26, 2024
Bought 322 K USD
Casdin Partners Master Fund, L.P.
director, 10 percent owner:
+ 150000
2.1497 USD
2 months ago
Aug 23, 2024
Bought 621 K USD
Casdin Partners Master Fund, L.P.
director, 10 percent owner:
+ 292100
2.1259 USD
2 months ago
Aug 22, 2024
Bought 603 K USD
Casdin Partners Master Fund, L.P.
director, 10 percent owner:
+ 307900
1.9578 USD
2 months ago
Aug 21, 2024
Bought 952 K USD
Casdin Partners Master Fund, L.P.
director, 10 percent owner:
+ 500000
1.9039 USD
2 months ago
Aug 20, 2024
Bought 937 K USD
Casdin Partners Master Fund, L.P.
director, 10 percent owner:
+ 500000
1.8734 USD
2 months ago
Aug 19, 2024
Bought 463 K USD
Casdin Partners Master Fund, L.P.
director, 10 percent owner:
+ 250000
1.8529 USD
3 months ago
Aug 14, 2024
Bought 1.91 M USD
Casdin Partners Master Fund, L.P.
director, 10 percent owner:
+ 1200000
1.5946 USD
3 months ago
Aug 13, 2024
Bought 891 K USD
Casdin Partners Master Fund, L.P.
director, 10 percent owner:
+ 550000
1.6192 USD
3 months ago
Aug 12, 2024
Bought 821 K USD
Casdin Partners Master Fund, L.P.
director, 10 percent owner:
+ 500000
1.6412 USD
3 months ago
Aug 09, 2024
Bought 848 K USD
Casdin Partners Master Fund, L.P.
director, 10 percent owner:
+ 525408
1.6149 USD
3 months ago
Aug 08, 2024
Bought 933 K USD
Casdin Partners Master Fund, L.P.
director, 10 percent owner:
+ 569562
1.6374 USD
3 months ago
Aug 07, 2024
Bought 786 K USD
Casdin Partners Master Fund, L.P.
director, 10 percent owner:
+ 500000
1.5724 USD
3 months ago
Aug 05, 2024
Bought 317 K USD
Casdin Partners Master Fund, L.P.
director, 10 percent owner:
+ 200000
1.5839 USD
3 months ago
Aug 02, 2024
Bought 1.63 M USD
Casdin Partners Master Fund, L.P.
director, 10 percent owner:
+ 1000000
1.6319 USD
5 months ago
May 23, 2024
Bought 260 K USD
Casdin Partners Master Fund, L.P.
director, 10 percent owner:
+ 100000
2.6 USD
5 months ago
May 22, 2024
Bought 388 K USD
Casdin Partners Master Fund, L.P.
director, 10 percent owner:
+ 150000
2.5849 USD
5 months ago
May 21, 2024
Bought 896 K USD
Casdin Partners Master Fund, L.P.
director, 10 percent owner:
+ 350000
2.5598 USD
5 months ago
May 20, 2024
Bought 258 K USD
Casdin Partners Master Fund, L.P.
director, 10 percent owner:
+ 100000
2.5813 USD
6 months ago
May 17, 2024
Bought 902 K USD
Casdin Partners Master Fund, L.P.
director, 10 percent owner:
+ 352072
2.5621 USD
6 months ago
May 16, 2024
Bought 1.27 M USD
Casdin Partners Master Fund, L.P.
director, 10 percent owner:
+ 500000
2.5419 USD
6 months ago
May 15, 2024
Bought 1.28 M USD
Casdin Partners Master Fund, L.P.
director, 10 percent owner:
+ 500000
2.5651 USD
8 months ago
Mar 05, 2024
Bought 3.67 K USD
Casdin Partners Master Fund, L.P.
director, 10 percent owner:
+ 1403
2.615 USD
8 months ago
Mar 04, 2024
Bought 642 K USD
Casdin Partners Master Fund, L.P.
director, 10 percent owner:
+ 250000
2.57 USD
1 year ago
May 19, 2023
Bought 97.2 K USD
Black Jeffrey G.
SVP & Chief Financial Officer
+ 42492
2.2878 USD
1 year ago
May 18, 2023
Bought 96.4 K USD
Black Jeffrey G.
SVP & Chief Financial Officer
+ 43492
2.2157 USD
1 year ago
May 19, 2023
Bought 1.84 M USD
Casdin Eli
director, 10 percent owner:
+ 800000
2.2949 USD
1 year ago
May 18, 2023
Bought 324 K USD
Casdin Eli
director, 10 percent owner:
+ 150000
2.1591 USD
1 year ago
May 17, 2023
Bought 472 K USD
Casdin Eli
director, 10 percent owner:
+ 250000
1.8862 USD
1 year ago
May 19, 2023
Bought 1.84 M USD
Casdin Partners Master Fund, L.P.
director, 10 percent owner:
+ 800000
2.2949 USD
1 year ago
May 18, 2023
Bought 324 K USD
Casdin Partners Master Fund, L.P.
director, 10 percent owner:
+ 150000
2.1591 USD
1 year ago
May 17, 2023
Bought 472 K USD
Casdin Partners Master Fund, L.P.
director, 10 percent owner:
+ 250000
1.8862 USD
2 years ago
Aug 04, 2022
Bought 447 K USD
Caligan Partners LP
10 percent owner
+ 255173
1.75 USD
2 years ago
Aug 03, 2022
Bought 80.1 K USD
JOHNSON DAVID EDWARD
director:
+ 46009
1.74 USD
2 years ago
Aug 03, 2022
Bought 80.1 K USD
Caligan Partners LP
10 percent owner
+ 46009
1.74 USD
2 years ago
Aug 02, 2022
Bought 447 K USD
Caligan Partners LP
10 percent owner
+ 272618
1.64 USD
2 years ago
Jul 29, 2022
Bought 311 K USD
JOHNSON DAVID EDWARD
director:
+ 210200
1.48 USD
2 years ago
Aug 01, 2022
Bought 311 K USD
Caligan Partners LP
10 percent owner
+ 210200
1.48 USD
2 years ago
Jul 29, 2022
Bought 195 K USD
Caligan Partners LP
10 percent owner
+ 137648
1.42 USD
2 years ago
Jun 13, 2022
Bought 170 K USD
Caligan Partners LP
10 percent owner, other: See Remarks
+ 100000
1.7 USD
2 years ago
Jun 13, 2022
Bought 170 K USD
JOHNSON DAVID EDWARD
director:
+ 100000
1.7 USD
2 years ago
Jun 03, 2022
Bought 495 K USD
Caligan Partners LP
10 percent owner
+ 250000
1.98 USD
2 years ago
Jun 02, 2022
Bought 384 K USD
Caligan Partners LP
10 percent owner
+ 200000
1.92 USD
2 years ago
Jun 02, 2022
Bought 384 K USD
JOHNSON DAVID EDWARD
director:
+ 200000
1.92 USD
2 years ago
May 10, 2022
Bought 63 K USD
Caligan Partners LP
10 percent owner
+ 25000
2.52 USD
2 years ago
May 06, 2022
Bought 1.34 M USD
Caligan Partners LP
10 percent owner
+ 463350
2.9 USD
2 years ago
May 06, 2022
Bought 1.34 M USD
JOHNSON DAVID EDWARD
director:
+ 463350
2.9 USD
2 years ago
Apr 28, 2022
Bought 351 K USD
JOHNSON DAVID EDWARD
director:
+ 125000
2.81 USD
2 years ago
Apr 28, 2022
Bought 351 K USD
JOHNSON DAVID EDWARD
director:
+ 125000
2.81 USD
2 years ago
Apr 29, 2022
Bought 658 K USD
Caligan Partners LP
10 percent owner
+ 247400
2.66 USD
2 years ago
Apr 28, 2022
Bought 66.2 K USD
Caligan Partners LP
10 percent owner
+ 27600
2.4 USD
2 years ago
Apr 11, 2022
Bought 180 K USD
JOHNSON DAVID EDWARD
director:
+ 50000
3.6 USD
2 years ago
Apr 12, 2022
Bought 180 K USD
Caligan Partners LP
10 percent owner
+ 50000
3.6 USD
2 years ago
Apr 11, 2022
Bought 561 K USD
Caligan Partners LP
10 percent owner
+ 145000
3.87 USD
2 years ago
Apr 08, 2022
Bought 752 K USD
Caligan Partners LP
10 percent owner
+ 200000
3.76 USD
2 years ago
Apr 07, 2022
Bought 776 K USD
Caligan Partners LP
10 percent owner
+ 200000
3.88 USD
2 years ago
Apr 06, 2022
Bought 776 K USD
JOHNSON DAVID EDWARD
director:
+ 200000
3.88 USD
2 years ago
Apr 06, 2022
Bought 394 K USD
Caligan Partners LP
10 percent owner
+ 109573
3.6 USD
3 years ago
Nov 23, 2020
Sell 514 K USD
Linthwaite Stephen Christopher
President & CEO
- 84820
6.06 USD
4 years ago
Mar 11, 2020
Bought 26.5 K USD
COLELLA SAMUEL D
Director
+ 10000
2.6545 USD
4 years ago
Mar 10, 2020
Bought 27.7 K USD
COLELLA SAMUEL D
Director
+ 10000
2.7738 USD
4 years ago
Mar 06, 2020
Bought 244 K USD
BARTHELEMY NICOLAS
Director
+ 80000
3.0484 USD
4 years ago
Feb 13, 2020
Bought 44.6 K USD
BARTHELEMY NICOLAS
Director
+ 12257
3.6399 USD
5 years ago
Sep 17, 2019
Sell 3.12 M USD
Levin Easterly Partners LLC
10 percent owner
- 577197
5.4 USD
5 years ago
Sep 11, 2019
Sell 8.38 K USD
Levin Easterly Partners LLC
10 percent owner
- 1507
5.564 USD
5 years ago
Sep 11, 2019
Sell 55.7 K USD
Levin Easterly Partners LLC
10 percent owner
- 10038
5.5516 USD
5 years ago
Aug 27, 2019
Bought 10.4 K USD
COLELLA SAMUEL D
Director
+ 2000
5.1859 USD
5 years ago
Aug 23, 2019
Bought 22.1 K USD
Linthwaite Stephen Christopher
President & CEO
+ 4000
5.5193 USD
7. News
Standard BioTools Appoints Alex Kim as Chief Financial Officer SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced the appointment of Alex Kim as Chief Financial Officer, effective November 11, 2024. Kim, a co-founder and most recently Chief Operating Officer of Standard BioTools, brings nearly 30 years of financial and operations experience in the healthcare and life sciences industries to the role and will oversee Standard BioTools' finance organization. globenewswire.com - 1 week ago
Standard BioTools to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that its management team will participate in the following investor conferences in the month of November: UBS Global Healthcare Conference on November 12 th , 2024 President and CEO, Michael Egholm, PhD, will participate in a corporate presentation on Tuesday, November 12, 2024, at 1:15 p.m. globenewswire.com - 2 weeks ago
Standard BioTools Inc. (LAB) Q3 2024 Earnings Call Transcript Standard BioTools Inc. (NASDAQ:LAB ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants David Holmes - IR Michael Egholm - President & CEO Alex Kim - Chief Operating Officer & Interim-CFO Conference Call Participants Matt Stanton - Jefferies Operator Good day and welcome to the Standard BioTools Inc Third Quarter 2024 Financial Results Conference Call. All participants will be in listen-only mode. seekingalpha.com - 2 weeks ago
Standard BioTools (LAB) Reports Q3 Loss, Tops Revenue Estimates Standard BioTools (LAB) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.15 per share a year ago. zacks.com - 2 weeks ago
Standard BioTools Reports Third Quarter 2024 Financial Results SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company”) today announced unaudited interim financial results for the third quarter ended September 30, 2024. globenewswire.com - 2 weeks ago
Standard BioTools Announces Conference Call and Webcast for Third Quarter 2024 Financial Results on October 30, 2024 SOUTH SAN FRANCISCO, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report third quarter 2024 financial results on Wednesday, October 30, 2024, after the close of the market. globenewswire.com - 1 month ago
GENOMMA LAB INTERNACIONAL ANNOUNCES NINTH DIVIDEND PAYMENT MEXICO CITY , Sept. 10, 2024 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. prnewswire.com - 2 months ago
Standard BioTools And 2 Other Penny Stocks Executives Are Buying The Dow Jones index closed higher by around 10 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. benzinga.com - 2 months ago
Standard BioTools And 3 Other Stocks Under $3 Executives Are Buying The Dow Jones index closed higher by around 0.2% on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. benzinga.com - 2 months ago
Standard BioTools to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), today announced that its management team will participate in the following investor conferences in the month of August: Canaccord Genuity 44th Annual Growth Conference on August 13th, 2024 President and CEO, Michael Egholm, PhD, will participate in a fireside chat on Tuesday, August 13, 2024, at 9:00 a.m. globenewswire.com - 3 months ago
Standard BioTools Inc. (LAB) Q2 2024 Earnings Call Transcript Standard BioTools Inc. (NASDAQ:LAB ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants David Holmes - IR Michael Egholm - President and CEO Jeff Black - CFO Conference Call Participants Matt Stanton - Jefferies Dan Brennan - TD Cowen Paul Knight - KeyBanc Operator Good day and welcome to the Standard BioTools Second Quarter 2024 Earnings Conference Call. All participants will be in listen-only mode. seekingalpha.com - 3 months ago
Standard BioTools (LAB) Reports Q2 Loss, Misses Revenue Estimates Standard BioTools (LAB) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.14 per share a year ago. zacks.com - 3 months ago
8. Profile Summary

Standard BioTools Inc. LAB

image
COUNTRY US
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 588 M
Dividend Yield 0.00%
Description Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
Contact 2 Tower Place, South San Francisco, CA, 94080 https://www.fluidigm.com
IPO Date Feb. 10, 2011
Employees 534
Officers Mr. Hanjoon Kim Interim Chief Financial Officer & Chief Operating Officer Dr. Michael Egholm Ph.D. President, Chief Executive Officer & Director